Literature DB >> 17124897

Higher order aberrations comparison in fellow eyes following intraLase LASIK with wavelight allegretto and customcornea LADArvision4000 systems.

Dan B Tran1, Viraj Shah.   

Abstract

PURPOSE: To compare the differences in objective and subjective visual outcomes with wavefront-optimized versus wavefront-guided excimer laser ablations using two different excimer laser platforms.
METHODS: In this prospective, randomized, matched, contralateral eye study, one eye was treated with the Alcon CustomCornea system, and the fellow eye was treated with the WaveLight Allegretto Wavefront-Optimized system. The IntraLase FS30 femtosecond laser was used to create all flaps. Treatments were randomized to the dominant eye, and optical treatment zones were matched to 6.5 mm. Patients were observed for 3 months after surgery. Initial data analysis was available for the first 28 eyes of 14 patients.
RESULTS: The only statistically significant differences between the groups were seen in the amount of higher order aberrations-the 14 eyes in the WaveLight group had a mean preoperative root-mean-square (RMS) error of 0.37 microm compared to 0.36 microm for 14 eyes in the Alcon group. Of the 8 patients who had 3-month follow-up, 8 eyes in the WaveLight group had a mean RMS error of 0.58 microm at 3 months, compared to 0.41 microm in the 8 eyes in the Alcon group.
CONCLUSIONS: Early results from this study have shown that both laser platforms produce accurate refractive outcomes; however, the Alcon CustomCornea LADARVision4000 system induces statistically significantly fewer higher order aberrations than the WaveLight Allegretto system.

Entities:  

Mesh:

Year:  2006        PMID: 17124897     DOI: 10.3928/1081-597X-20061101-25

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  7 in total

Review 1.  [Application of wavefront analysis in clinical and scientific settings. From irregular astigmatism to aberrations of a higher order--Part II: examples].

Authors:  J Bühren; T Kohnen
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

2.  [Wavefront aberrations and subjective quality of vision after wavefront-guided LASIK: first results].

Authors:  J Bühren; A Strenger; T Martin; T Kohnen
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

3.  A prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave ® Eye-Q versus VISX CustomVue™ STAR S4 IR™ in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations.

Authors:  Majid Moshirfar; Brent S Betts; Daniel S Churgin; Maylon Hsu; Marcus Neuffer; Shameema Sikder; Dane Church; Mark D Mifflin
Journal:  Clin Ophthalmol       Date:  2011-09-20

4.  Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations.

Authors:  Majid Moshirfar; Daniel S Churgin; Brent S Betts; Maylon Hsu; Shameema Sikder; Marcus Neuffer; Dane Church; Mark D Mifflin
Journal:  Clin Ophthalmol       Date:  2011-08-22

5.  One-year eye-to-eye comparison of wavefront-guided versus wavefront-optimized laser in situ keratomileusis in hyperopes.

Authors:  Christopher S Sáles; Edward E Manche
Journal:  Clin Ophthalmol       Date:  2014-11-12

Review 6.  Outcome comparison between wavefront-guided and wavefront-optimized photorefractive keratectomy: A systematic review and meta-analysis.

Authors:  Khaled M Hamam; Mohamed I Gbreel; Randa Elsheikh; Amira Y Benmelouka; Yassamine Ouerdane; Amr K Hassan; Aboalmagd Hamdallah; Ahmed B Elsnhory; Anas Z Nourelden; Ahmed T Masoud; Asmaa A Ali; Khaled M Ragab; Ahmed M Ibrahim
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

7.  Induced Higher-order aberrations after Laser In Situ Keratomileusis (LASIK) Performed with Wavefront-Guided IntraLase Femtosecond Laser in moderate to high Astigmatism.

Authors:  Ferial M Al-Zeraid; Uchechukwu L Osuagwu
Journal:  BMC Ophthalmol       Date:  2016-03-22       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.